Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

cal activity and survival.

Ron Bentsur, CEO of Keryx, commented, "The data presented at the ASH meeting further demonstrate perifosine's potential beyond the ongoing Phase 3 registration trials in metastatic colorectal cancer and multiple myeloma. It is encouraging to see perifosine's activity as a single agent and in combination with sorafenib in heavily pre-treated, advanced CLL and HL patients, respectively. Moreover, the perifosine-Revlimid® (+ dexamethasone) combination data in multiple myeloma also presented at ASH indicate that the combination is well tolerated demonstrating promising clinical activity."

Perifosine is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.  Both of these Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA, and with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 Thoratec Corporation (NASDAQ: ... therapies to save, support and restore failing hearts, said ... th Annual Healthcare Conference on Tuesday, June 9. ... Chief Executive Officer, will provide an update on the ... p.m., Eastern Daylight Time). The presentation will ...
(Date:5/26/2015)... 2015   Mallinckrodt Pharmaceuticals (NYSE: MNK ... it has extended the deadline for submitting applications to ... The program awards grants to help fund projects in ... Research Fellowship Awards program is designed to further scientific ... will award a total of 25 positions. The program ...
(Date:5/26/2015)... CITY , May 26, 2015 /PRNewswire/ ... warehousing and analytics, today launched Health ... designed to help health systems build the ... quality and operational efficiency. ... in Health Catalyst,s comprehensive suite of outcomes-improvement ...
Breaking Medicine Technology:Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 2Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 3Introducing Health Catalyst Academy: An Innovative Approach for Accelerating Outcomes Improvement 2Introducing Health Catalyst Academy: An Innovative Approach for Accelerating Outcomes Improvement 3Introducing Health Catalyst Academy: An Innovative Approach for Accelerating Outcomes Improvement 4
(Date:5/26/2015)... Rochester, MN (PRWEB) May 26, 2015 ... years of debilitating nosebleeds and fainting spells, four of ... even leading to cardiac arrest. , Though she ... transfusion, she continues to dedicate her time to increasing ... mission. , “Had there been awareness, we could have ...
(Date:5/26/2015)... May 26, 2015 The American College of ... them for the Open House/Free Application Day on Wednesday, July ... until 4 p.m. and will be held at ACTCM Pioneer ... , After checking in, attendees will be greeted with an ... tour of the campus at 11:45 a.m. Lunch will be ...
(Date:5/26/2015)... May 26, 2015 Abington is ... Wellness, a physician practice with seven medical professionals, ... the eighth primary-care site in the United States ... medical home by the National Committee for Quality ... primary, preventative and sick care – including routine ...
(Date:5/26/2015)... 2015 It was an evening befitting ... Colorado. On Wednesday, May 13, The Denver Foundation marked ... era of community-based giving with its Annual Celebration, held ... the Making,” the event celebrated the donors, leaders, grantees, ... mobilize resources for good. , “If your organization, neighborhood ...
(Date:5/26/2015)... 26, 2015 Allprovide, the all-natural raw ... all-natural dog foods are now available in three Georgia ... and The Good Old Dog Company in Kennesaw. , ... recently opened a state-of-the-art, climate controlled facility. The fresh ... and all of the food is triple-tested for quality. ...
Breaking Medicine News(10 mins):Health News:Rochester Woman Brings Awareness to Genetic Disease 2Health News:ACTCM to Host Summer Open House 2Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2
... ... ... ... , ...
... ... ... ... ...
... CINCINNATIResearchers at the University of Cincinnati (UC) Interstitial Lung Disease ... and Blood Institute to study ways ILD first appears in ... efficiently diagnose and treat it. ILD is a group ... of the airways, like asthma and emphysema do. It causes ...
... 25, 2010 Profoundly deaf children with cochlear implants to ... to their normal-hearing peers, according to new research from UT ... a child is implanted with a cochlear device and the ... quality of life the child reports and the more successful ...
... ... growth at the Parallels Summit 2010 , ... Miami, FL (PRWEB) February 23, 2010 -- Worldwide cloud enablement ... the Parallels Summit 2010., , ,Highlighting excellence in the industry, the awards recognize the ...
... With nearly 50,000 killed a year, better infection control ... (HealthDay News) -- Sepsis and pneumonia caused by hospital-acquired ... in increased health care costs in the United States ... called Extending the Cure. , The project examining antibiotic ...
Cached Medicine News:Health News:Kimberly-Clark Announces 10 Percent Dividend Increase 2Health News:Kimberly-Clark Announces 10 Percent Dividend Increase 3Health News:Guardian Offers Critical Illness Insurance Advice 2Health News:Guardian Offers Critical Illness Insurance Advice 3Health News:Guardian Offers Critical Illness Insurance Advice 4Health News:Guardian Offers Critical Illness Insurance Advice 5Health News:Guardian Offers Critical Illness Insurance Advice 6Health News:Researchers receive NIH grant to study predictors and outcomes of autoimmune lung disease 2Health News:Deaf children with cochlear implants report similar quality of life to that of normal-hearing kids 2Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 2Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 3Health News:Hospital-Acquired Sepsis, Pneumonia a 'Growing Menace' 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: